Ahmedabad, India (August 25, 2021) — Switzerland-based Company’s subsidiary, CARBOGEN AMCIS AG., a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the signing of a co- investment agreement with one of its key European customers. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and follows a previous investment of CHF 6 million.
The co-investment totals CHF 4 million and will be focussed on expanding capacities to support the market introduction of the customer’s lead compound. The investment at the CARBOGEN AMCIS AG. Neuland location includes the addition of a medium pressure chromatography column (200L),a preparative 20 cm HPLC system and short path distillation equipment.
“We are committed to providing our customers with the best technologies and this investment willallow our client to benefit from state-of-the-art equipment that enables expanded manufacturing capacity to commercialization scale-up, and getting a much-needed drug to patients,” said Stephan Fritschi, VP operations, CARBOGEN AMCIS AG.
This agreement follows an earlier CHF 6 million investment made in 2017 by the same customer at the CARBOGEN AMCIS AG.’ Neuland location.
The collaboration between the two companies spans more than 10 years and started during the project’s pre-clinical development stage. “We have supported our client from the early stages of pre-clinical development all the way through to routine commercial manufacture. We are proud to be part of our customer’s successful journey towards product commercialization and this co-investment is the latest milestone in our long-standing partnership,” said Pascal Villemagne, VP sales and marketing, CARBOGEN AMCIS AG.
CARBOGEN AMCIS AG.’ Neuland location specializes in early phase development and rapid kg API supply to GMPs. Its strong analytical capabilities and crystallization lab can serve up numerous customers simultaneously. The recent chromatography equipment addition reinforces the extensive offerings available at this site.
The equipment is expected to be ready for production by Q1 2023.
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Carbogen Amcis Limited., Ahmedabad, India.
For further information please visit the website https://imdcal.com/or contact:
Veritas Reputation PR
Veritas Reputation PR